MX337070B - Método para preparar un conjugado klh-egfrviii. - Google Patents

Método para preparar un conjugado klh-egfrviii.

Info

Publication number
MX337070B
MX337070B MX2012007283A MX2012007283A MX337070B MX 337070 B MX337070 B MX 337070B MX 2012007283 A MX2012007283 A MX 2012007283A MX 2012007283 A MX2012007283 A MX 2012007283A MX 337070 B MX337070 B MX 337070B
Authority
MX
Mexico
Prior art keywords
vaccine compositions
methods
present disclosure
compositions
composistions
Prior art date
Application number
MX2012007283A
Other languages
English (en)
Other versions
MX2012007283A (es
Inventor
Syed Saleem Ahmed
John Joseph Buckley Iii
Lavina Marina Lewis
Brandi Rae Osborne
Sandipan Sinha
Jennifer Marie Thorn
Ferhana Zaman
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of MX2012007283A publication Critical patent/MX2012007283A/es
Publication of MX337070B publication Critical patent/MX337070B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método preparar un conjugado KLH-EGFRvIII que comprende: a) combinar KLH con un conector de entrecruzamiento bifuncional y dejar que KLH y el conector interactúen durante un tiempo que varía de 30 x 60 minutos; b) agregar un péptido que comprende la SEQ ID NO: 1 al producto de KLH activado resultante de la etapa a) para proporcionar el conjugado KLH-EGFRvIII, en donde la relación molar conector:KLH varia de 75:1 a 325:1. Un conjugado KLH-EGFRvIII producido por el método de caracterizado porque dicho conjugado presenta una densidad de epítopes en el rango de 20-80, determinando mediante el análisis de la composición de aminoácidos.
MX2012007283A 2009-12-22 2010-12-08 Método para preparar un conjugado klh-egfrviii. MX337070B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
PCT/IB2010/055674 WO2011077309A2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Publications (2)

Publication Number Publication Date
MX2012007283A MX2012007283A (es) 2012-07-30
MX337070B true MX337070B (es) 2016-02-11

Family

ID=43797591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007283A MX337070B (es) 2009-12-22 2010-12-08 Método para preparar un conjugado klh-egfrviii.

Country Status (13)

Country Link
US (3) US20130034573A1 (es)
EP (2) EP2515934B1 (es)
JP (2) JP6007105B2 (es)
KR (1) KR20120120185A (es)
CN (2) CN102762224A (es)
AU (1) AU2010334428B2 (es)
CA (1) CA2785585A1 (es)
IL (1) IL220308A0 (es)
MX (1) MX337070B (es)
NZ (2) NZ629256A (es)
RU (1) RU2581020C2 (es)
SG (2) SG181628A1 (es)
WO (1) WO2011077309A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102970988B (zh) * 2010-02-21 2016-03-16 拜耳医药保健有限公司 用于活化和缀合生物分子的方法
KR101502360B1 (ko) * 2013-03-20 2015-03-25 주식회사 옵티팜 신규한 국내형 돼지생식기호흡기증후군 바이러스
AU2019305221A1 (en) 2018-07-19 2021-02-18 Helixmith Co., Ltd. Lyophilized pharmaceutical compositions for naked DNA gene therapy

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (es) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ATE135373T1 (de) 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
JP4620808B2 (ja) * 1994-11-28 2011-01-26 トーマス・ジェファーソン・ユニバーシティ 突然変異上皮成長因子受容体を標的とする試薬および方法
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
PT1005368E (pt) 1997-03-10 2009-11-19 Coley Pharm Gmbh Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
DE69819150T3 (de) 1997-06-06 2007-12-20 Dynavax Technologies Corp., San Diego Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2214722T3 (es) * 1997-07-31 2004-09-16 Metra Biosystems, Inc. Metodo de ensayo de peptidos de colageno.
ATE505478T1 (de) * 1997-08-27 2011-04-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkalen b epitopen
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
AU783344B2 (en) 1999-02-17 2005-10-20 Csl Limited Immunogenic complexes and methods relating thereto
WO2000056360A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against antigens from bacteriae
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥ｃ反応性タンパク質組成物
IL145982A0 (en) 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
CN1391483A (zh) 1999-09-24 2003-01-15 史密丝克莱恩比彻姆生物有限公司 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用
AR025749A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
EP1475101B1 (en) * 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
ES2352668T3 (es) * 2002-08-14 2011-02-22 Mitsubishi Chemical Medience Corporation Anticuerpo específico para una proteína tau del sistema nervioso central.
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
AU2004260936B2 (en) * 2003-06-27 2010-06-10 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
DK1684719T3 (da) * 2003-11-14 2012-01-30 Baxter Int Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger
CA2572427A1 (en) 2004-07-18 2006-01-18 Heather L. Davis Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
WO2006134423A2 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
AU2006284248B2 (en) * 2005-05-24 2010-10-07 Neovacs A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFalpha and a carrier protein
CN104857500A (zh) * 2005-11-02 2015-08-26 杜克大学 同时的化学疗法和免疫疗法
AU2008287340A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
BRPI0821474B8 (pt) * 2007-12-28 2021-05-25 Baxalta GmbH formulação farmacêutica líquida estável

Also Published As

Publication number Publication date
JP2013515049A (ja) 2013-05-02
JP6146927B2 (ja) 2017-06-14
US20130034573A1 (en) 2013-02-07
US20190365886A1 (en) 2019-12-05
EP3257525A3 (en) 2018-02-28
RU2012131162A (ru) 2014-01-27
RU2581020C2 (ru) 2016-04-10
SG10201408505SA (en) 2015-02-27
EP2515934A2 (en) 2012-10-31
IL220308A0 (en) 2012-07-31
EP3257525A2 (en) 2017-12-20
SG181628A1 (en) 2012-07-30
JP6007105B2 (ja) 2016-10-12
CN102762224A (zh) 2012-10-31
EP2515934B1 (en) 2017-05-17
KR20120120185A (ko) 2012-11-01
US20150087815A1 (en) 2015-03-26
AU2010334428A1 (en) 2012-07-05
WO2011077309A2 (en) 2011-06-30
AU2010334428B2 (en) 2015-05-21
NZ629256A (en) 2016-02-26
JP2015180667A (ja) 2015-10-15
CA2785585A1 (en) 2011-06-30
MX2012007283A (es) 2012-07-30
WO2011077309A3 (en) 2011-10-06
NZ600978A (en) 2014-08-29
CN107412754A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
MX339769B (es) Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos.
MX2011007930A (es) Conjugados de insulina cristalina.
MY152711A (en) Oral compositions containing a combination of natural extracts and related methods
AU2016204319A1 (en) Methods and compositions for producing squalene using yeast
MY165955A (en) Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
WO2010111409A3 (en) Pluripotent stem cells
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
MX2012005782A (es) Procedimientos, composiciones y kits de liofilizacion.
MX2013001045A (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
SG196784A1 (en) Stem cell cultures
MX2011013700A (es) Cepa talaromyces y composiciones de enzimas.
WO2010088633A3 (en) Novel cell lines and methods
MX2011003473A (es) Composiciones para el cuidado bucal.
WO2010120785A3 (en) Methods and compositions for stem cell cultures
MX2010000348A (es) Cultivo de celulas madre pluripotentes individuales.
IN2012DN01898A (es)
WO2011159770A3 (en) Methods and compositions for promoting hair growth
IN2012DN00581A (es)
PH12014501369A1 (en) Oral care compositions
MY161601A (en) Films and compositions comprising the same
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX2013007230A (es) Sistemas de polimero.
IN2012DN03404A (es)
EP2435558A4 (en) PRODUCTION OF HEAVY INDUCED PLURIPOTENT STEM CELLS GENERALLY CORRECTED

Legal Events

Date Code Title Description
FG Grant or registration